[Alpha Tau in Alpha Tau] Alpha Tau submits first pre-market approval module to the FDA for Alpha DaRT® for the treatment of recurrent cutaneous squamous cell carcinoma (cSCC)

Jerusalem, January 5, 2026 – Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”, or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT^® today announced the submission of the first module of its pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA), following the FDA’s previous decision to allow the Company to use the more flexible modular approach.

Read more here.